Saito Y, Motoyoshi Y, Kashima K, Izumiyama-Shimomura N, Toda T, Nakano I, Hasegawa M, Murayama S.	Unique tauopathy in Fukuyama-type congenital muscular dystrophy.	J Neuropath Exp Neurol	64	1118-1126	2005
Kano H, Kurosawa K, Horii E, Ikegawa S, Yoshikawa H, Kurahashi H, Toda T.	Genomic rearrangement at 10q24 in non-syndromic split-hand/split-foot malformation.	Hum Genet	118	477-483	2005
Toda T, Chiyonobu T, Xiong H, Tachikawa M, Kobayashi K, Manya H, Takeda S, Taniguchi M, Kurahashi H, Endo T.	Fukutin and alpha-dystroglycanopahties.	Acta Myologica	24	60-63	2005
Kariya S, Hirano M, Uesato S, Nagai Y, Nagaoka Y, Furiya Y, Asai H, Fujikake N, Toda T, Ueno S.	Cytoprotective effect of novel histone deacetylase inhibitors against polyglutamine toxicity.	Neurosci Lett	392	213-215	2006
Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, Kitami T, Sato K, Kuroda R, Tomiyama H, Mizoguchi K, Murata M, Toda T, Imoto I, Inazawa J, Mizuno Y, Hattori N.	Clinical heterogeneity of a-synuclein gene duplication in Parkinson's disease.	Ann Neurol	59	298-309	2006
Taniguchi M, Kurahashi H, Noguchi S, Sese J, Okinaga T, Tsukahara T, Guicheney P, Ozono K, Nishino I, Morishita S, Toda T.	Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-a2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease?	Biochem Biophys Res Commun	344	489-502	2006
Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, Nagai Y,	Multiple candidate gene analysis identifies {alpha}-synuclein as a susceptibility gene for sporadic	Hum Mol Genet	15	1151-1158	2006

Oka A, Inoko H, Fukae J, Saito Y, Sawabe M, Murayama S, Yamamoto M, Hattori N, Murata M, Toda T.	Parkinson's disease.				
Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T, Lu CS, Inzelberg R, Djaldetti R, Melamed E, Amouri R, Gouider-Khouja N, Hentati F, Hatano Y, Wang M, Imamichi Y, Mizoguchi K, Miyajima H, Obata F, Toda T, Farrer MJ, Mizuno Y, Hattori N.	Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.	Mov Disord.	(in press)		
Miyachi S, Lu X, Inoue S, Iwasaki T, Koike S, Nambu A, Takada M.	Organization of multisynaptic inputs from prefrontal cortex to primary motor cortex as revealed by retrograde transneuronal transport of rabies virus.	J Neurosci	25	2547-2556	2005
Kita H, Tachibana Y, Nambu A, Chiken S.	Balance of monosynaptic excitatory and disynaptic inhibitory responses of the globus pallidus induced after stimulation of the subthalamic nucleus in the monkey.	J Neurosci	25	8611-8619	2005
Kaneda K, Tachibana Y, Imanishi M, Kita H, Shigemoto R, Nambu A, Takada M.	Downregulation of metabotropic glutamate receptor 1a in globus pallidus and substantia nigra of parkinsonian monkeys.	Eur J Neurosci	22	3241-3254	2005
Hatanaka N, Tokuno H, Nambu A, Inoue T, Takada M.	Input-output organization of jaw movement-related areas in monkey frontal cortex.	J Comp Neurol	492	401-425	2005
Nambu A.	A new approach to understand the pathophysiology of Parkinson's disease.	J Neurol	252 (S4)	1-4	2005
Nakatsuka A, Nagai	Effect of clarithromycin on the	Journal of	100	59-64	2006

M, Yabe H, Nishikawa N, Nomura T, Moritoyo H, Moritoyo T, Nomoto M.	pharmacokinetics of cabergoline in the healthy controls and in patients with Parkinson's disease.	Pharmacologic al Sciences			
Nomoto M.	Pharmacological consideration of the symptoms resistant to dopaminergic therapy.	Parkinsonism and related disoreders	(in press)		
Nomoto M, Nagai M.	Proteasome Function and Pathological Proteins in the Pathogenesis of Parkinson's Disease.	Journal of Pharmacologic al Sciences	97	455-456	2005
Ohta E, Toyoshima I, Funayama M, Ichinose H, Hasegawa K, Obata F.	A new mutation (Thr106Ile) of the GTP cyclohydrolase 1 gene associated with DYT5 dystonia (Segawa disease).	Mov Disord.	20	1083-1084	2005
Moore DJ, Zhang L, Troncoso J, Lee MK, Hattori N, Mizuno Y, Dawson TM, Dawson VL.	Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress.	Hum Mol Genet	14	71-84	2005
Clarimon J, Johnson J, Djaldetti R, Hernandez D,Hattori N, Sroka H, Barhom Y, Singleton A.	Mutation of the Parkin gene in a Persian family: Clinical progression over a 40-year period.	Mov Disord	20 (7)	887-890	2005
Suzuki M, Hattori N, Orimo S, Fukumitsu N, Abo M, Kono Y, Sengoku R, Kurita A, Honda H, Inoue K.	Preserved myocardial [(123)I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: First case report.	Mov Disord	20 (5)	634-636	2005
Noda K, Kitami T, Gai WP, Chegini F, Jensen PH, Fujimura T, Murayama K, Tanaka K, Mizuno Y, Hattori N.	Phosphorylated IkappaBalpha is a component of Lewy body of Parkinson's disease.	Biochem Biophys Res Commun	331 (1)	309-17	2005
Fukae J, Takanashi M, Kubo S, Nishioka K, Nakabeppu Y, Mori H, Yoshikuni M,	Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders.	Acta Neuropathol	109	256-262	2005

Hattori N.					
Fukae J, Kubo S, Hattori N, Komatsu K, Kato M, Aoki M, Mizuno Y.	Hoarseness due to bilateral vocal cord paralysis as an initial manifestation of familial amyotrophic lateral sclerosis.	Amyotrophic lateral sclerosis	6	122-124	2005
Sato S, Mizuno Y, Hattori N.	Urinary8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease.	Neurology	64 (6)	1081-3	2005
Li G, Kitami T, Wang M, Mizuno Y, Hattori N.	Geographic and ethnic differences in frequencies of two polymorphisms (D/N394 and L/I272) of the parkin gene in sporadic Parkinson's disease.	Parkinsonism and related Disord	11	485-491	2005
Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, Edwards RH, Fortin DL.	A combinatoriual code for the interaction of a-synuclein with membranes.	J Biol Chem	9 (36)	280 31664-72	2005
Orimo S, Amino T, Yokochi M, Kojo T, Uchihara T, Takahashi A, Wakabayashi K, Takahashi H, Hattori N, Mizuno Y.	Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2.	Mov Disord	20	1350-1353	2005
Yamamoto S, Fukae J, Mori H, Mizuno Y, Hattori N.	Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.	Neuroscience Lett	396	187-191	2006
Sato S, Chiba T, Sakata E, Kato K, Mizuno Y, Hattori N, Tanaka K.	14-3-3 eta is a novel regulator of parkin ubiquitin-ligase.	EMBO J	11	211-221	2006
Wang YL, Liu W, Wada E, Murata M, Wada K, Kanazawa I.	Clinico-pathological rescue of a model mouse of Huntigton's disease by siRNA.	Neurosci Res	53	241-249	2005
浅沼幹人, 宮崎育子.	薬物依存・毒性発現にかかわる分子の分子生物学的検索法—網羅的プロファイリングを中心に.	日本薬理学雑誌	126	30-34	2005
浅沼幹人.	ドパミン受容体アゴニストによるドパミンニューロン死の制御	Clinical Neuroscience	23	1342-1343	2005

浅沼幹人, 小川紀雄.	酸化ストレスによる神経障害と神経保護療法―ドパミン神経特異的酸化ストレスとしてのキノン体毒性.	医学のあゆみ	215	785-792	2005
中塚晶子, 野元正弘.	健康食品による健康被害.	日本醫事新報	4225	23-25	2005
永井将弘, 野元正弘.	腎の薬物トランスポーターと薬物代謝.	日本醫事新報	4251	18-20	2005
野元正弘,中塚晶子,永井将弘,矢部勇人,森豊隆志,森豊浩代子,西川典子.	パーキンソン病治療の個人差と薬物動態.	臨床神経	45	895-898	2005
岡本和士, 紀平為子, 近藤智善, 阪本尚正, 小橋元, 鷲尾昌一, 三宅吉博, 槿山徹司, 佐々木敏, 稲葉裕.	筋萎縮性側策硬化症患者におけるQOLの変化とその関連要因に関する検討.	厚生の指標	52	29-33	2005
近藤智善.	神経内科で遭遇する様々な不随意運動―その診断と治療―.	和歌山県醫師会医学雑誌	34	30-32	2005
近藤智善.	パーキンソン病とインフォームド・コンセント.	Modern Physician	25	995-998	2005
中西一郎, 近藤智善.	現在の治療戦略 L-ドーパ開始時期と長期維持のポイント―病気を受容し明るい見通しをもってもらうために―.	Modern Physician	25	945-951	2005
近藤智善.	パーキンソン病患者の下肢筋力増強訓練の効果解析.	脳21	8(3)	116-120	2005
近藤智善.	パーキンソン病の治療と生活―症状の特徴と診断のための検査―.	毎日ライフ	36 (8)	28-34	2005
近藤智善.	パーキンソン病の治療と生活―治療の種類と症状の抑え方―.	毎日ライフ	36 (8)	35-50	2005
近藤智善.	パーキンソン病の治療と生活―日常生活のトラブル対処法―.	毎日ライフ	36 (8)	51-56	2005
戸田達史.	新たな時代にいかにして多因子疾患に迫るか.	Mol Med	42	1194-1196	2005
戸田達史.	フクチン fukutin(FCMD).	生体の科学	56	514-515	2005
長谷川一子.	パーキンソン病の治療.		423	5-11	2005
長谷川一子.	今日のパーキンソン病の診療 診断の基本から治療の最前線まで.	モダンフィジシン	25 (8)	1019-1023	2005

	今後期待される，新たなパーキンソン病治療薬.				
村田美穂.	パーキンソン病の診断基準・病型分類・重症度　内科疾患の診断基準・病型分類・重症度.	内科	95 (6)	1531-1536	2005
村田美穂.	今日のパーキンソン病の診療—パーキンソン病治療のポイント　パーキンソン病治療ガイドラインと tailor made 治療.	Modern Physician	25 (8)	941-944	2005
村田美穂.	特集：神経難病のリハビリテーション　パーキンソン病. 総合リハビリテーション	医学書院	33(8)	709-712	2005
村田美穂.	外来診療での神経・筋疾患患者の訴えのとらえ方　ふるえる、けいれんする	診断と治療社	93(8	1252-1255	2005